A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer

Inclusion Criteria: * Epithelial carcinoma of ovarian, peritoneal or fallopian tube origin. * Female * age above 18 years * WHO performance status 0-2 * Life expectancy \> 3 months * Previous treatment with one platinum and taxane containing regimen. * Platinum and taxane sensitive relapse * At least one evaluable/measurable lesion. * Adequate hematologic, renal and liver function * Consent form signed and dated before inclusion Exclusion Criteria: * Prior treatment with more than one line of chemotherapy * Concurrent severe and/or uncontrolled co-morbid medical condition. * History of previous or concurrent malignancy within the previous 5 years • History of prior serious allergic reactions such as anaphylactic shock * Pregnant or lactating women (or potentially fertile women not using adequate contraception) * Peripheral neuropathy \> Grade 2 * History of allergy to drugs containing the excipient TWEEN 80®. * Concomitant administration of any other experimental drug under investigation or concurrent treatment with any other anti-cancer therapy * Clinical evidence of brain metastases